$72.80
0.510.71%
At close: Aug 21, 5:00 PM EST
$72.54
-0.26-0.36%
After Hours: 8:55 AM EST
Tools
Free Benzinga Pro Trial
Calendars
Trade Ideas
Short Interest
Calculators
Compare Best Stocks
State Street SPDR S&P Pharmaceuticals ETF (XPH) Stock Price, Quote, News & History
XPHARCA
Edge Rankings
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
Sector
Healthcare
Region
US
AUM
570.56M
Fund Score
Loading...
Key Statistics
Open
$72.84
High
$73.35
52 Wk High
$74.35
AUM
570.56M
Dividend
$0.35
Ex-Div Date
Jun 22, 2026
Volume
83.8K
Market Cap
$38.46B
Mgmt Fee
0.35%
P/E Ratio
13.48
Prev. Close
$72.29
Low
$72.68
52 Wk Low
$45.80
Shares Out
4.85M
Yield
0.48%
Div. Freq
-
Avg. Volume Daily
100.85K
Beta
0.58
Avg. Expense Ratio
0.35%
P/B Ratio
3.01
Recent State Street SPDR S&P Pharmaceuticals ETF News
FAQ
Q
How do I buy State Street SPDR S&P Pharmaceuticals ETF (XPH) stock?
A
You can purchase shares of State Street SPDR S&P Pharmaceuticals ETF (ARCA:XPH) through any online brokerage.
Q
Who are State Street SPDR S&P Pharmaceuticals ETF (XPH) competitors?
A
There are no as such competitors for State Street SPDR S&P Pharmaceuticals ETF.
Q
What is the forecast, or price target, for State Street SPDR S&P Pharmaceuticals ETF (XPH) stock?
A
There is no analysis for State Street SPDR S&P Pharmaceuticals ETF to provide a consensus price target.
Q
What is the current price for State Street SPDR S&P Pharmaceuticals ETF (XPH)?
A
The stock price for State Street SPDR S&P Pharmaceuticals ETF (ARCA: XPH) is $72.5415 last updated August 21, 2026 at 8:55 AM EDT.
Q
Does State Street SPDR S&P Pharmaceuticals ETF (XPH) pay a dividend?
A
There are no upcoming dividends for State Street SPDR S&P Pharmaceuticals ETF.
Q
When is State Street SPDR S&P Pharmaceuticals ETF (ARCA:XPH) reporting earnings?
A
State Street SPDR S&P Pharmaceuticals ETF does not have any upcoming earnings scheduled.
Q
Is State Street SPDR S&P Pharmaceuticals ETF (XPH) going to split?
A
There is no upcoming split for State Street SPDR S&P Pharmaceuticals ETF.
Key Statistics
Open
$72.84
High
$73.35
52 Wk High
$74.35
AUM
570.56M
Dividend
$0.35
Ex-Div Date
Jun 22, 2026
Volume
83.8K
Market Cap
$38.46B
Mgmt Fee
0.35%
P/E Ratio
13.48
Prev. Close
$72.29
Low
$72.68
52 Wk Low
$45.80
Shares Out
4.85M
Yield
0.48%
Div. Freq
-
Avg. Volume Daily
100.85K
Beta
0.58
Avg. Expense Ratio
0.35%
P/B Ratio
3.01
About
Sector
N/A
Industry
N/A
ETF Details
| Sector | Healthcare |
| Category | Mid Performer-Mid Growth |
| Investment Style | Mid Cap Blend |
| Fund Inception | Jun 19, 2006 |
| Managers | Keith Richardson Karl A. Schneider |
| Definition | Most of the stocks in this equity fund have average financial performance and average growth potential |
Investment Policy
In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the index), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index (S&P TMI).
Top ETF Holdings
| Symbol | Name | Share % |
|---|---|---|
| CA | Definium Therapeutics,... | 2.88% |
| ELVN | Enliven Therapeutics I... | 2.04% |
| TRVI | Trevi Therapeutics Inc... | 2.02% |
| MBX | Mbx Biosciences Inc | 2.81% |
| ALMS | Alumis Inc Common Stoc... | 2.05% |
| AMLX | Amylyx Pharmaceuticals... | 2.01% |
| MAZE | Maze Therapeutics Inc | 1.98% |
| MANE | Veradermics Inc | 1.98% |
| ATAI | Ataibeckley Inc. | 1.98% |
| LGND | Ligand Pharmaceuticals... | 1.95% |
Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API
Market data provided by Benzinga APIs
Market Resources
Trading Tools & Education
- Benzinga Pro Trading Platform
- Options Trading Strategies and News
- Stock Market Trading Ideas and Analysis
- Technical Analysis Charts and Indicators
- Fundamental Analysis and Valuation
- Day Trading Guides and Strategies
- Live Investor Events
- Pre-market Stock Analysis and News
- Cryptocurrency Market Analysis and News
Ring the Bell
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
© 2026 Benzinga | All Rights Reserved